Compare · INCR vs NVS
INCR vs NVS
Side-by-side comparison of Intercure Ltd. (INCR) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INCR and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $285.38B, about 5735.2x INCR ($49.8M).
- Over the past year, INCR is down 34.5% and NVS is up 31.0% - NVS leads by 65.5 points.
- NVS has hit the wire 1 time in the past 4 weeks while INCR has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 1 for INCR).
- Company
- Intercure Ltd.
- Novartis AG
- Price
- $0.98-1.77%
- $149.50-2.75%
- Market cap
- $49.8M
- $285.38B
- 1M return
- +12.39%
- -0.88%
- 1Y return
- -34.51%
- +30.97%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 1
- Recent ratings
- 1
- 25
Intercure Ltd.
InterCure Ltd, together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest INCR
- SEC Form 6-K filed by Intercure Ltd.
- InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
- SEC Form 6-K filed by Intercure Ltd.
- InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
- SEC Form 6-K filed by Intercure Ltd.
- InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
- SEC Form 20-F filed by Intercure Ltd.
- SEC Form 3 filed by new insider Rabinovich Alexander
- SEC Form 3 filed by new insider Michelson Lennie Grinbaum
- SEC Form 3 filed by new insider Granot Alon Shmuel
Latest NVS
- SEC Form 6-K filed by Novartis AG
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG